Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1981 1
1982 2
1983 1
1984 2
1985 1
1986 6
1987 10
1988 12
1989 15
1990 33
1991 41
1992 31
1993 48
1994 59
1995 67
1996 93
1997 118
1998 117
1999 131
2000 135
2001 179
2002 258
2003 300
2004 325
2005 476
2006 499
2007 529
2008 697
2009 805
2010 892
2011 1066
2012 1235
2013 1415
2014 1820
2015 2137
2016 2447
2017 2724
2018 3252
2019 3615
2020 4336
2021 4972
2022 5826
2023 5770
2024 1349

Text availability

Article attribute

Article type

Publication date

Search Results

42,872 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for beijing lu
Search for Feiling Lu instead (1 results)
Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy.
Xu M, Zhang P, Ding J, Chen J, Huo L, Liu Z. Xu M, et al. J Nucl Med. 2022 Jun;63(6):952-958. doi: 10.2967/jnumed.121.262533. Epub 2021 Sep 30. J Nucl Med. 2022. PMID: 34593598 Free PMC article.
PET imaging, SPECT imaging, and biodistribution studies were performed to evaluate the pharmacokinetics in pancreatic cancer patient-derived xenograft (PDX) animal models. The cancer treatment efficacy of (177)Lu-TEFAPI-06 and (177)Lu-TEFAPI-07 were evaluated in pan …
PET imaging, SPECT imaging, and biodistribution studies were performed to evaluate the pharmacokinetics in pancreatic cancer patient-derived …
Erythema Elevatum Diutinum.
Liu J, Lu S. Liu J, et al. Am J Med Sci. 2022 Mar;363(3):e21-e22. doi: 10.1016/j.amjms.2021.07.012. Epub 2021 Sep 20. Am J Med Sci. 2022. PMID: 34547285 No abstract available.
Theranostic application of (64)Cu/(177)Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models.
Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, Zhou D, Wang R, Gong J, Miao Q, Kang L, Yang J. Li C, et al. Eur J Nucl Med Mol Imaging. 2022 Dec;50(1):168-183. doi: 10.1007/s00259-022-05954-y. Epub 2022 Sep 5. Eur J Nucl Med Mol Imaging. 2022. PMID: 36063202
Flow cytometry and cell immunofluorescence were used to evaluate the binding ability of hIMB1636 and Trop2 on the cell surface. hIMB1636 were conjugated with p-SCN-Bn-NOTA (NOTA) and DOTA-NHS-ester (DOTA) for (64)Cu and (177)Lu radiolabeling respectively. ImmunoPET imaging …
Flow cytometry and cell immunofluorescence were used to evaluate the binding ability of hIMB1636 and Trop2 on the cell surface. hIMB1636 wer …
[(177)Lu]Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models.
Zeng Z, Li L, Tao J, Liu J, Li H, Qian X, Yang Z, Zhu H. Zeng Z, et al. Eur J Nucl Med Mol Imaging. 2023 Dec 8. doi: 10.1007/s00259-023-06561-1. Online ahead of print. Eur J Nucl Med Mol Imaging. 2023. PMID: 38062170
RESULTS: [(177)Lu]Lu-TST001 was labeled with an 99.17%0.32 radiochemical purity, an 18.50 1.27 MBq/nmol specific activity and a stability of 94% after 7 days. ...CONCLUSION: In preclinical studies, [(177)Lu]Lu-TST001 demonstrated significant antitumor …
RESULTS: [(177)Lu]Lu-TST001 was labeled with an 99.17%0.32 radiochemical purity, an 18.50 1.27 MBq/nmol specific activity and …
Optimized Therapeutic (177)Lu-Labeled PSMA-Targeted Ligands with Improved Pharmacokinetic Characteristics for Prostate Cancer.
Wu Y, Zhang X, Duan X, Yang X, Wang F, Zhang J. Wu Y, et al. Pharmaceuticals (Basel). 2022 Dec 9;15(12):1530. doi: 10.3390/ph15121530. Pharmaceuticals (Basel). 2022. PMID: 36558981 Free PMC article.
Clinical trials have shown the significant efficacy of [(177)Lu]Lu-PSMA-617 for treating prostate cancer. However, the pharmacokinetic characteristics and therapeutic performance of [(177)Lu]Lu-PSMA-617 still need further improvement to meet clinical e …
Clinical trials have shown the significant efficacy of [(177)Lu]Lu-PSMA-617 for treating prostate cancer. However, the pharmac …
Reply.
Li H, Lu XZ. Li H, et al. J Ultrasound Med. 2018 Jul;37(7):1850. doi: 10.1002/jum.14505. Epub 2017 Dec 23. J Ultrasound Med. 2018. PMID: 29274084 No abstract available.
Unraveling the mystery of dreams.
Lin X, Han Y, Lu L. Lin X, et al. J Thorac Dis. 2017 Sep;9(9):2732-2735. doi: 10.21037/jtd.2017.07.103. J Thorac Dis. 2017. PMID: 29221226 Free PMC article. No abstract available.
Gene Therapy on the Road.
Feng YM. Feng YM. Curr Gene Ther. 2019;19(1):6. doi: 10.2174/1566523219999190426144513. Curr Gene Ther. 2019. PMID: 31190640
Erratum.
[No authors listed] [No authors listed] Interv Neuroradiol. 2015 Feb;21(1):137-8. doi: 10.1177/1591019915576685. Interv Neuroradiol. 2015. PMID: 25934789 Free PMC article.
Stent fracture and occlusion after treatment of symptomatic vertebral artery ostium stenosis with a self-expanding device: A case report by Jun Lu, Jiachun Liu, Daming Wang and Shuo Wang, Interventional Neuroradiology 2014 20: 755-760, DOI: 10.15274/INR-2014-10068. In the …
Stent fracture and occlusion after treatment of symptomatic vertebral artery ostium stenosis with a self-expanding device: A case report by …
Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG.
Ma S, Jiang W, Liu X, Lu WJ, Qi T, Wei J, Wu F, Chang Y, Zhang S, Song Y, Bai R, Wang J, Lee AS, Zhang H, Wang Y, Lan F. Ma S, et al. Circ Res. 2021 Oct 29;129(10):895-908. doi: 10.1161/CIRCRESAHA.120.318674. Epub 2021 Sep 16. Circ Res. 2021. PMID: 34525843 Free article.
42,872 results
You have reached the last available page of results. Please see the User Guide for more information.